Oaktree Capital Management, L.P. 13F holdings and portfolio analysis
Sign in to clone a new branch from the selected plan, then continue optimizing in the new branch.
Baseline
Analysis messagesPre-generated Q&A about this fund. Use as reference context for your own analysis.
The strongest recent period was 2021-12-31 (10.99% strategy return, -5.97% benchmark, 16.96% excess, 12.55% turnover), while the weakest was 2024-06-30 (3.57% strategy return, 12.13% benchmark, -8.57% excess, 15.94% turnover). Those periods should be read alongside baseline metrics of return 6.92%, alpha 1.91%, beta 0.39, Sharpe 0.56, Sortino 0.58, and max drawdown -45.31% to judge whether returns came from persistent exposure or a narrow timing window.
The latest change list shows AU unchanged to 50.60%; INDV unchanged to 23.24%; CBL unchanged to 10.06%. Combined with top 5 96.28%, top 10 99.31%, top 20 100.02%, that tells the user whether the baseline is becoming more concentrated or simply refreshing existing exposure. For a static page, this is the best first check before deciding whether the raw disclosed book is still acceptable.
Concentration is the first item to inspect: top 5 96.28%, top 10 99.31%, top 20 100.02%. The largest names are AU (AngloGold Ashanti plc) 50.60%, INDV (Indivior Pharmaceuticals, Inc.) 23.24%, CBL 10.06%, STKL (SunOpta Inc.) 7.18%, and OACC (Oaktree Acquisition Corp. III Life Sciences) 5.20%, and the largest sector exposures are Materials 50.60%, Health Care 24.71%, and Real Estate 10.06%. If those exposures reverse, baseline performance can diverge sharply from a broad index.